{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:20:29Z","timestamp":1788542429437,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["MH107615"],"award-info":[{"award-number":["MH107615"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1I01BX004062"],"award-info":[{"award-number":["1I01BX004062"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["101BX003631"],"award-info":[{"award-number":["101BX003631"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41386-025-02085-4","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T14:26:04Z","timestamp":1742221564000},"page":"928-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rapid hippocampal synaptic potentiation induced by ketamine metabolite (2R,6R)-hydroxynorketamine persistently primes synaptic plasticity"],"prefix":"10.1038","volume":"50","author":[{"given":"Kyle A.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa I.","family":"Ajibola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1511-7183","authenticated-orcid":false,"given":"Todd D.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"2085_CR1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"2085_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","volume":"74","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74:250\u201356.","journal-title":"Biol Psychiatry"},{"key":"2085_CR3","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","volume":"25","author":"M Fava","year":"2020","unstructured":"Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25:1592\u2013603.","journal-title":"Mol Psychiatry"},{"key":"2085_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharm Rev. 2018;70:621\u201360.","journal-title":"Pharm Rev"},{"key":"2085_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.molmed.2023.02.003","volume":"29","author":"J-W Kim","year":"2023","unstructured":"Kim J-W, Suzuki K, Kavalali ET, Monteggia LM. Bridging rapid and sustained antidepressant effects of ketamine. Trends Mol Med. 2023;29:364\u201375.","journal-title":"Trends Mol Med"},{"key":"2085_CR6","doi-asserted-by":"crossref","unstructured":"Brown KA, Gould TD. Targeting metaplasticity mechanisms to promote sustained antidepressant actions. Mol Psychiatry. 2024:29:1114\u201327.","DOI":"10.1038\/s41380-023-02397-1"},{"key":"2085_CR7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2305772120","volume":"120","author":"JH Krystal","year":"2023","unstructured":"Krystal JH, Kaye AP, Jefferson S, Girgenti MJ, Wilkinson ST, Sanacora G, et al. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proc Natl Acad Sci USA. 2023;120:e2305772120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2085_CR8","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/s41386-018-0136-3","volume":"43","author":"CG Abdallah","year":"2018","unstructured":"Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GM, et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018;43:2154\u201360.","journal-title":"Neuropsychopharmacology"},{"key":"2085_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/mp.2017.58","volume":"23","author":"I Esterlis","year":"2018","unstructured":"Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C] ABP688 and PET imaging study in depression. Mol Psychiatry. 2018;23:824\u201332.","journal-title":"Mol Psychiatry"},{"key":"2085_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/mp.2016.34","volume":"22","author":"GM Chowdhury","year":"2017","unstructured":"Chowdhury GM, Zhang J, Thomas M, Banasr M, Ma X, Pittman B, et al. Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry. 2017;22:120\u201326.","journal-title":"Mol Psychiatry"},{"key":"2085_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0306-4522(02)00652-8","volume":"117","author":"D Lorrain","year":"2003","unstructured":"Lorrain D, Baccei C, Bristow L, Anderson J, Varney M. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience. 2003;117:697\u2013706.","journal-title":"Neuroscience"},{"key":"2085_CR12","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","volume":"17","author":"B Moghaddam","year":"1997","unstructured":"Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921\u201327.","journal-title":"J Neurosci"},{"key":"2085_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould T. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23:801\u201311.","journal-title":"Mol Psychiatry"},{"key":"2085_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.31887\/DCNS.2014.16.1\/rduman","volume":"16","author":"RS Duman","year":"2014","unstructured":"Duman RS. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci. 2014;16:11\u201327.","journal-title":"Dialogues Clin Neurosci"},{"key":"2085_CR15","doi-asserted-by":"crossref","unstructured":"Kavalali ET, Monteggia LM. Rapid homeostatic plasticity and neuropsychiatric therapeutics. Neuropsychopharmacology. 2023;48:54\u201360.","DOI":"10.1038\/s41386-022-01411-4"},{"key":"2085_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.ado7010","volume":"385","author":"M Chen","year":"2024","unstructured":"Chen M, Ma S, Liu H, Dong Y, Tang J, Ni Z, et al. Brain region\u2013specific action of ketamine as a rapid antidepressant. Science. 2024;385:eado7010.","journal-title":"Science"},{"key":"2085_CR17","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41586-023-06624-1","volume":"622","author":"S Ma","year":"2023","unstructured":"Ma S, Chen M, Jiang Y, Xiang X, Wang S, Wu Z, et al. Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb. Nature. 2023;622:802\u201309.","journal-title":"Nature"},{"key":"2085_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature25509","volume":"554","author":"Y Yang","year":"2018","unstructured":"Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554:317\u201322.","journal-title":"Nature"},{"key":"2085_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-pharmtox-010617-052811","volume":"59","author":"TD Gould","year":"2019","unstructured":"Gould TD, Zarate CA Jr., Thompson SM. Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. Annu Rev Pharm Toxicol. 2019;59:213\u201336.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"2085_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1124\/pharmrev.120.000149","volume":"73","author":"JN Highland","year":"2021","unstructured":"Highland JN, Zanos P, Riggs LM, Georgiou P, Clark SM, Morris PJ, et al. Hydroxynorketamines: pharmacology and potential therapeutic applications. Pharm Rev. 2021;73:763\u201391.","journal-title":"Pharm Rev"},{"key":"2085_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481\u20136.","journal-title":"Nature"},{"key":"2085_CR22","doi-asserted-by":"crossref","unstructured":"Raja SM, Guptill JT, Mack M, Peterson M, Byard S, Twieg R, et al. A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2 R, 6 R)\u2010Hydroxynorketamine in Healthy Volunteers. Clin Pharmacol Ther. 2024;116:1314\u201324.","DOI":"10.1002\/cpt.3391"},{"key":"2085_CR23","doi-asserted-by":"crossref","unstructured":"Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, et al. (2R, 6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions. Proc Natl Acad Sci USA. 2019;116:6441\u201350.","DOI":"10.1073\/pnas.1819540116"},{"key":"2085_CR24","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1124\/dmd.109.027011","volume":"37","author":"F Dutheil","year":"2009","unstructured":"Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellott\u00e9e L, et al. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Disposition. 2009;37:1528\u201338.","journal-title":"Drug Metab Disposition"},{"key":"2085_CR25","doi-asserted-by":"crossref","unstructured":"Brown KA, Zanos P, Powels CF, Fix CJ, Michaelides M, Pereira EF, et al. Ketamine preservative benzethonium chloride potentiates hippocampal synaptic transmission and binds neurotransmitter receptors and transporters. Neuropharmacology. 2023;225:109403.","DOI":"10.1016\/j.neuropharm.2022.109403"},{"key":"2085_CR26","doi-asserted-by":"crossref","unstructured":"Riggs LM, Aracava Y, Zanos P, Fischell J, Albuquerque EX, Pereira EFR, et al. (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. Neuropsychopharmacology. 2020;45:426\u201336.","DOI":"10.1038\/s41386-019-0443-3"},{"key":"2085_CR27","doi-asserted-by":"crossref","unstructured":"Riggs LM, Thompson SM, Gould TD. (2R, 6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity. Neuropharmacology. 2022:109153.","DOI":"10.1016\/j.neuropharm.2022.109153"},{"key":"2085_CR28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41593-022-01146-x","volume":"25","author":"P Georgiou","year":"2022","unstructured":"Georgiou P, Zanos P, Mou T-CM, An X, Gerhard DM, Dryanovski DI, et al. Experimenters\u2019 sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor. Nat Neurosci. 2022;25:1191\u2013200.","journal-title":"Nat Neurosci"},{"key":"2085_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119707","volume":"279","author":"KA Brown","year":"2021","unstructured":"Brown KA, Carpenter JM, Preston CJ, Ludwig HD, Clay KB, Harn DA, et al. Lacto-N-fucopentaose-III ameliorates acute and persisting hippocampal synaptic plasticity and transmission deficits in a Gulf War Illness mouse model. Life Sci. 2021;279:119707.","journal-title":"Life Sci"},{"key":"2085_CR30","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1523\/JNEUROSCI.1316-22.2022","volume":"43","author":"P Zanos","year":"2023","unstructured":"Zanos P, Brown KA, Georgiou P, Yuan P, Zarate CA, Thompson SM, et al. NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine. J Neurosci. 2023;43:1038\u201350.","journal-title":"J Neurosci"},{"key":"2085_CR31","doi-asserted-by":"crossref","unstructured":"Thompson SM. Plasticity of synapses and reward circuit function in the genesis and treatment of depression. Neuropsychopharmacology. 2023;48:90\u2013103.","DOI":"10.1038\/s41386-022-01422-1"},{"key":"2085_CR32","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1073\/pnas.1816071116","volume":"116","author":"EW Lumsden","year":"2019","unstructured":"Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, et al. Antidepressant-relevant concentrations of the ketamine metabolite (2 R, 6 R)-hydroxynorketamine do not block NMDA receptor function. Proc Natl Acad Sci USA. 2019;116:5160\u201369.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2085_CR33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1021\/acschemneuro.1c00761","volume":"13","author":"JN Highland","year":"2022","unstructured":"Highland JN, Morris PJ, Konrath KM, Riggs LM, Hagen NR, Zanos P, et al. Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2, 6)-and (5 R)-Methyl-(2 R, 6 R)-hydroxynorketamines. ACS Chem Neurosci. 2022;13:510\u201323.","journal-title":"ACS Chem Neurosci"},{"key":"2085_CR34","doi-asserted-by":"crossref","unstructured":"Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, et al. (R)\u2010Ketamine exerts antidepressant actions partly via conversion to (2R, 6R)\u2010hydroxynorketamine, while causing adverse effects at sub\u2010anaesthetic doses. Br J Pharmacol. 2019;176:2573\u201392.","DOI":"10.1111\/bph.14683"},{"key":"2085_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0269881118812095","volume":"33","author":"JN Highland","year":"2019","unstructured":"Highland JN, Morris PJ, Zanos P, Lovett J, Ghosh S, Wang AQ, et al. Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R, 6R)-hydroxynorketamine. J Psychopharmacol. 2019;33:12\u201324.","journal-title":"J Psychopharmacol"},{"key":"2085_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1152\/jn.00326.2023","volume":"131","author":"LM Riggs","year":"2024","unstructured":"Riggs LM, Pereira EF, Thompson SM, Gould TD. cAMP-dependent protein kinase signaling is required for (2R, 6R)-hydroxynorketamine to potentiate hippocampal glutamatergic transmission. J Neurophysiol. 2024;131:64\u201374.","journal-title":"J Neurophysiol"},{"key":"2085_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0896-6273(00)80210-X","volume":"17","author":"L-E Trudeau","year":"1996","unstructured":"Trudeau L-E, Emery DG, Haydon PG. Direct modulation of the secretory machinery underlies PKA-dependent synaptic facilitation in hippocampal neurons. Neuron. 1996;17:789\u201397.","journal-title":"Neuron"},{"key":"2085_CR38","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1523\/JNEUROSCI.0999-04.2004","volume":"24","author":"M Kaneko","year":"2004","unstructured":"Kaneko M, Takahashi T. Presynaptic mechanism underlying cAMP-dependent synaptic potentiation. J Neurosci. 2004;24:5202\u201308.","journal-title":"J Neurosci"},{"key":"2085_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1152\/physrev.00013.2021","volume":"102","author":"KF Ostrom","year":"2022","unstructured":"Ostrom KF, LaVigne JE, Brust TF, Seifert R, Dessauer CW, Watts VJ, et al. Physiological roles of mammalian transmembrane adenylyl cyclase isoforms. Physiol Rev. 2022;102:815\u201357.","journal-title":"Physiol Rev"},{"key":"2085_CR40","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.neuroscience.2007.01.045","volume":"146","author":"AC Conti","year":"2007","unstructured":"Conti AC, Maas JrJW, Muglia LM, Dave BA, Vogt SK, Tran TT, et al. Distinct regional and subcellular localization of adenylyl cyclases type 1 and 8 in mouse brain. Neuroscience. 2007;146:713\u201329.","journal-title":"Neuroscience"},{"key":"2085_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-022-00322-2","volume":"19","author":"K Devasani","year":"2022","unstructured":"Devasani K, Yao Y. Expression and functions of adenylyl cyclases in the CNS. Fluids Barriers CNS. 2022;19:23.","journal-title":"Fluids Barriers CNS"},{"key":"2085_CR42","doi-asserted-by":"publisher","first-page":"eaah5381","DOI":"10.1126\/scisignal.aah5381","volume":"10","author":"TF Brust","year":"2017","unstructured":"Brust TF, Alongkronrusmee D, Soto-Velasquez M, Baldwin TA, Ye Z, Dai M, et al. Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties. Sci Signal. 2017;10:eaah5381.","journal-title":"Sci Signal"},{"key":"2085_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13041-020-00627-z","volume":"13","author":"LR Aleksandrova","year":"2020","unstructured":"Aleksandrova LR, Wang YT, Phillips AG. Ketamine and its metabolite,(2R, 6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression. Mol Brain. 2020;13:1\u201316.","journal-title":"Mol Brain"},{"key":"2085_CR44","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S0006-3223(00)00935-5","volume":"48","author":"RS Duman","year":"2000","unstructured":"Duman RS, Malberg J, Nakagawa S, D\u2019Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry. 2000;48:732\u20139.","journal-title":"Biol Psychiatry"},{"key":"2085_CR45","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1146\/annurev-neuro-110920-040422","volume":"45","author":"PK Parekh","year":"2022","unstructured":"Parekh PK, Johnson SB, Liston C. Synaptic Mechanisms Regulating Mood State Transitions in Depression. Annu Rev Neurosci. 2022;45:581\u2013601.","journal-title":"Annu Rev Neurosci"},{"key":"2085_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112378","volume":"380","author":"JW Kim","year":"2020","unstructured":"Kim JW, Monteggia LM. Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways. Behav Brain Res. 2020;380:112378.","journal-title":"Behav Brain Res"},{"key":"2085_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109918","volume":"37","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Kim J-W, Nosyreva E, Kavalali ET, Monteggia LM. Convergence of distinct signaling pathways on synaptic scaling to trigger rapid antidepressant action. Cell Rep. 2021;37:109918.","journal-title":"Cell Rep"},{"key":"2085_CR48","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.neuropharm.2014.08.002","volume":"86","author":"Y Izumi","year":"2014","unstructured":"Izumi Y, Zorumski CF. Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function. Neuropharmacology. 2014;86:273\u201381.","journal-title":"Neuropharmacology"},{"key":"2085_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.brainres.2015.03.019","volume":"1609","author":"JD Graef","year":"2015","unstructured":"Graef JD, Newberry K, Newton A, Pieschl R, Shields E, Luan FN, et al. Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus. Brain Res. 2015;1609:31\u20139.","journal-title":"Brain Res"},{"key":"2085_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.brainres.2014.03.004","volume":"1560","author":"PO Ribeiro","year":"2014","unstructured":"Ribeiro PO, Tom\u00e9 AR, Silva HB, Cunha RA, Antunes LM. Clinically relevant concentrations of ketamine mainly affect long-term potentiation rather than basal excitatory synaptic transmission and do not change paired-pulse facilitation in mouse hippocampal slices. Brain Res. 2014;1560:10\u201317.","journal-title":"Brain Res"},{"key":"2085_CR51","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41386-020-0714-z","volume":"45","author":"BK Chen","year":"2020","unstructured":"Chen BK, Luna VM, LaGamma CT, Xu X, Deng SX, Suckow RF, et al. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine. Neuropsychopharmacology. 2020;45:1545\u201356.","journal-title":"Neuropsychopharmacology"},{"key":"2085_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112153","volume":"376","author":"AJ Polis","year":"2019","unstructured":"Polis AJ, Fitzgerald PJ, Hale PJ, Watson BO. Rodent ketamine depression-related research: Finding patterns in a literature of variability. Behav Brain Res. 2019;376:112153.","journal-title":"Behav Brain Res"},{"key":"2085_CR53","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/jpet.105.091199","volume":"316","author":"CR Maxwell","year":"2006","unstructured":"Maxwell CR, Ehrlichman RS, Liang Y, Trief D, Kanes SJ, Karp J, et al. Ketamine produces lasting disruptions in encoding of sensory stimuli. J Pharm Exp Ther. 2006;316:315\u201324.","journal-title":"J Pharm Exp Ther"},{"key":"2085_CR54","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.biopsych.2015.04.022","volume":"79","author":"RA Brachman","year":"2016","unstructured":"Brachman RA, McGowan JC, Perusini JN, Lim SC, Pham TH, Faye C, et al. Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior. Biol Psychiatry. 2016;79:776\u201386.","journal-title":"Biol Psychiatry"},{"key":"2085_CR55","doi-asserted-by":"publisher","first-page":"9710","DOI":"10.1523\/JNEUROSCI.23-30-09710.2003","volume":"23","author":"H Wang","year":"2003","unstructured":"Wang H, Pineda VV, Chan GC, Wong ST, Muglia LJ, Storm DR. Type 8 adenylyl cyclase is targeted to excitatory synapses and required for mossy fiber long-term potentiation. J Neurosci. 2003;23:9710\u201318.","journal-title":"J Neurosci"},{"key":"2085_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1215255","volume":"17","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wang H. Ca2+-stimulated ADCY1 and ADCY8 regulate distinct aspects of synaptic and cognitive flexibility. Front Cell Neurosci. 2023;17:1215255.","journal-title":"Front Cell Neurosci"},{"key":"2085_CR57","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1101\/lm.030114.112","volume":"20","author":"M Zhang","year":"2013","unstructured":"Zhang M, Wang H. Mice overexpressing type 1 adenylyl cyclase show enhanced spatial memory flexibility in the absence of intact synaptic long-term depression. Learn Mem. 2013;20:352\u201357.","journal-title":"Learn Mem"},{"key":"2085_CR58","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/s41380-018-0083-8","volume":"24","author":"NH Wray","year":"2019","unstructured":"Wray NH, Schappi JM, Singh H, Senese NB, Rasenick MM. NMDAR-independent, cAMP-dependent antidepressant actions of ketamine. Mol Psychiatry. 2019;24:1833\u201343.","journal-title":"Mol Psychiatry"},{"key":"2085_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.949384","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen J, Ding Q, An L, Wang H. Ca2+-stimulated adenylyl cyclases as therapeutic targets for psychiatric and neurodevelopmental disorders. Front Pharm. 2022;13:949384.","journal-title":"Front Pharm"},{"key":"2085_CR60","doi-asserted-by":"crossref","unstructured":"Kang H, Park P, Han M, Tidball P, Georgiou J, Bortolotto ZA, et al. (2 S, 6 S)-and (2 R, 6 R)-hydroxynorketamine inhibit the induction of NMDA receptor-dependent LTP at hippocampal CA1 synapses in mice. Brain and Neuroscience Advances. 2020;4:2398212820957847.","DOI":"10.1177\/2398212820957847"},{"key":"2085_CR61","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/309261a0","volume":"309","author":"ML Mayer","year":"1984","unstructured":"Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature. 1984;309:261\u201363.","journal-title":"Nature"},{"key":"2085_CR62","doi-asserted-by":"publisher","first-page":"a005710","DOI":"10.1101\/cshperspect.a005710","volume":"4","author":"C L\u00fcscher","year":"2012","unstructured":"L\u00fcscher C, Malenka RC. NMDA receptor-dependent long-term potentiation and long-term depression (LTP\/LTD). Cold Spring Harb Perspect Biol. 2012;4:a005710.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2085_CR63","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejphar.2012.11.023","volume":"698","author":"R Moaddel","year":"2013","unstructured":"Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, et al. Sub-anesthetic concentrations of (R, S)-ketamine metabolites inhibit acetylcholine-evoked currents in \u03b17 nicotinic acetylcholine receptors. Eur J Pharm. 2013;698:228\u201334.","journal-title":"Eur J Pharm"},{"key":"2085_CR64","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1021\/acs.orglett.7b02177","volume":"19","author":"PJ Morris","year":"2017","unstructured":"Morris PJ, Moaddel R, Zanos P, Moore CE, Gould T, Zarate JrCA, et al. Synthesis and N-methyl-d-aspartate (NMDA) receptor activity of ketamine metabolites. Org Lett. 2017;19:4572\u20135.","journal-title":"Org Lett"},{"key":"2085_CR65","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1038\/nature22084","volume":"546","author":"K Suzuki","year":"2017","unstructured":"Suzuki K, Nosyreva E, Hunt KW, Kavalali ET, Monteggia LM. Effects of a ketamine metabolite on synaptic NMDAR function. Nature. 2017;546:E1\u20133.","journal-title":"Nature"},{"key":"2085_CR66","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1523\/JNEUROSCI.1655-19.2020","volume":"40","author":"JR Barnes","year":"2020","unstructured":"Barnes JR, Mukherjee B, Rogers BC, Nafar F, Gosse M, Parsons MP. The relationship between glutamate dynamics and activity-dependent synaptic plasticity. J Neurosci. 2020;40:2793\u2013807.","journal-title":"J Neurosci"},{"key":"2085_CR67","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1073\/pnas.1814709116","volume":"116","author":"K Fukumoto","year":"2019","unstructured":"Fukumoto K, Foga\u00e7a MV, Liu R-J, Duman C, Kato T, Li X-Y, et al. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2 R, 6 R)-hydroxynorketamine. Proc Natl Acad Sci USA. 2019;116:297\u2013302.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2085_CR68","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrn3353","volume":"13","author":"LN Cooper","year":"2012","unstructured":"Cooper LN, Bear MF. The BCM theory of synapse modification at 30: interaction of theory with experiment. Nat Rev Neurosci. 2012;13:798\u2013810.","journal-title":"Nat Rev Neurosci"},{"key":"2085_CR69","doi-asserted-by":"publisher","first-page":"10924","DOI":"10.1073\/pnas.181342098","volume":"98","author":"WC Abraham","year":"2001","unstructured":"Abraham WC, Mason-Parker SE, Bear MF, Webb S, Tate WP. Heterosynaptic metaplasticity in the hippocampus in vivo: a BCM-like modifiable threshold for LTP. Proc Natl Acad Sci. 2001;98:10924\u201329.","journal-title":"Proc Natl Acad Sci"},{"key":"2085_CR70","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fnbeh.2012.00085","volume":"6","author":"A Buschler","year":"2012","unstructured":"Buschler A, Manahan-Vaughan D. Brief environmental enrichment elicits metaplasticity of hippocampal synaptic potentiation in vivo. Front Behav Neurosci. 2012;6:85.","journal-title":"Front Behav Neurosci"},{"key":"2085_CR71","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0166-2236(96)80018-X","volume":"19","author":"WC Abraham","year":"1996","unstructured":"Abraham WC, Bear MF. Metaplasticity: the plasticity of synaptic plasticity. Trends Neurosci. 1996;19:126\u201330.","journal-title":"Trends Neurosci"},{"key":"2085_CR72","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1126\/science.1346729","volume":"255","author":"Y-Y Huang","year":"1992","unstructured":"Huang Y-Y, Colino A, Selig DK, Malenka RC. The influence of prior synaptic activity on the induction of long-term potentiation. Science. 1992;255:730\u201333.","journal-title":"Science"},{"key":"2085_CR73","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/npp.2012.246","volume":"38","author":"J Burgdorf","year":"2013","unstructured":"Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2013;38:729\u201342.","journal-title":"Neuropsychopharmacology"},{"key":"2085_CR74","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fnbeh.2018.00229","volume":"12","author":"Y Yang","year":"2018","unstructured":"Yang Y, Ju W, Zhang H, Sun L. Effect of ketamine on LTP and NMDAR EPSC in hippocampus of the chronic social defeat stress mice model of depression. Front Behav Neurosci. 2018;12:229.","journal-title":"Front Behav Neurosci"},{"key":"2085_CR75","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fnsyn.2018.00008","volume":"10","author":"AJ Widman","year":"2018","unstructured":"Widman AJ, Stewart AE, Erb EM, Gardner E, McMahon LL. Intravascular ketamine increases theta-burst but not high frequency tetanus induced LTP at CA3-CA1 synapses within three hours and devoid of an increase in spine density. Front Synaptic Neurosci. 2018;10:8.","journal-title":"Front Synaptic Neurosci"},{"key":"2085_CR76","doi-asserted-by":"crossref","unstructured":"Kim J-W, Autry AE, Na ES, Adachi M, Bj\u00f6rkholm C, Kavalali ET, et al. Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation. Nat Neurosci. 2021;24:1100\u201309.","DOI":"10.1038\/s41593-021-00868-8"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02085-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T08:03:31Z","timestamp":1745568211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02085-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2085"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02085-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.18.619152","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TDG is listed as co-author in patents and patent applications related to the pharmacology and use of (\n                      2R,6R\n                      )-HNK in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders.\u00a0TDG has assigned his patent rights to the University of Maryland, Baltimore, but will share a percentage of any royalties that may be received by the University of Maryland, Baltimore. The contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. TDG has served as a consultant for Boehringer Ingelheim during the preceding 3 years. All other authors report no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}